Omega Funds
Omega Funds is a venture capital firm focused on investing in the future of medicine. The firm emphasizes delivering transformative medicines to patients and reports helping bring 52 products to market. Omega also acts as an advisor to certain European funds.
Omega Funds
Services
Equity investments (Seed to Series A and beyond)
Provides capital across early stages (seed) through Series A and later financings; press items cite Omega-led seed rounds and participation in Series A launches.
Advisory services to funds and portfolio companies
Acts as an advisor to certain European funds and provides strategic support to portfolio companies to advance medicines to patients.
Network access and industry connections
Provides entrepreneurs access to industry connections and networks to increase the odds of commercial and clinical success.
Support focused on delivering medicines to patients
Investment process emphasizes end‑game patient impact and advancing programs toward clinical proof-of-concept and commercialization.
Equity investments (Seed to Series A and beyond)
Provides capital across early stages (seed) through Series A and later financings; press items cite Omega-led seed rounds and participation in Series A launches.
Advisory services to funds and portfolio companies
Acts as an advisor to certain European funds and provides strategic support to portfolio companies to advance medicines to patients.
Network access and industry connections
Provides entrepreneurs access to industry connections and networks to increase the odds of commercial and clinical success.
Support focused on delivering medicines to patients
Investment process emphasizes end‑game patient impact and advancing programs toward clinical proof-of-concept and commercialization.
Portfolio
Launch reported with $200 million Series A to develop a long-acting anti-TSLP antibody (press item dated 25 Jun 2025).
#Biotechnology / Therapeutics (anti-TSLP antibody)
Launch reported with $177 million to develop first-in-class precision medicines (press item dated 10 Jun 2025).
#Precision medicines / Oncology
Press item reports closing of a $65 million underwritten public offering (3 Jun 2025).
#Biopharma / Therapeutics
Announced $80 million equity financing to advance genetic medicines for cardiovascular diseases (27 May 2025).
#Genetic medicines / Cardiovascular
Seed financing led by Omega Funds reported (6 May 2025).
#Therapeutics / Obesity treatment
Agreement for Boston Scientific to acquire SoniVie Ltd. announced (3 Mar 2025).
#Medical technology / Therapeutics (acquired)
Launch reported with $200 million Series A to develop a long-acting anti-TSLP antibody (press item dated 25 Jun 2025).
#Biotechnology / Therapeutics (anti-TSLP antibody)
Launch reported with $177 million to develop first-in-class precision medicines (press item dated 10 Jun 2025).
#Precision medicines / Oncology
Press item reports closing of a $65 million underwritten public offering (3 Jun 2025).
#Biopharma / Therapeutics
Announced $80 million equity financing to advance genetic medicines for cardiovascular diseases (27 May 2025).
#Genetic medicines / Cardiovascular
Seed financing led by Omega Funds reported (6 May 2025).
#Therapeutics / Obesity treatment
Agreement for Boston Scientific to acquire SoniVie Ltd. announced (3 Mar 2025).
#Medical technology / Therapeutics (acquired)